Healthcare - Page 4
Latest
AI Screened 6,680 Molecules and Helped Find a New Antibiotic, Abaucin
An AI model ranked 6,680 compounds in under two hours and helped find abaucin, which treated superbug infections in mice. It isn't a medicine yet.
Fudan-Led AI Builds Rare Gut-Lesion Training Images From One Photo
EndoRare, a Fudan-led AI model in Nature Communications, makes varied images of four rare gut conditions from one photo to train classifiers and novices.
St Jude Says Its Open-Source MyGPT AI Can Run on a $1,839 Mac Mini
St Jude researchers have published MyGPT, an open-source AI that answers questions from private documents without sending data outside the building.
Uganda Tests Drones to Fly Island Lab Samples to Kampala in 90 Minutes
Uganda's health ministry has tested drones to carry lab samples from the Kalangala islands to Kampala, where road and boat trips can take days.
Alliance Medinet Breach Hit Data of 110,000 Members, Parent Says
Alliance Healthcare says personal data of about 110,000 Alliance Medinet members was compromised. Insurers name those affected and what to do next.
KRAS Pancreatic Cancer Vaccine Misses Main Goal but Primes T Cells
An off-the-shelf KRAS vaccine missed its main goal in a 144-patient pancreatic cancer trial, but 89 of 90 evaluable patients mounted a T-cell response.
Early NIH-Led Trial Finds T-Cell Drug Invika Stalls Resistant Tumours
In an early trial led by NIH researchers, T-cell drug invika stopped cancer growing in 16 of 27 patients at the optimal dose and shrank tumours in four.
Google Says Partner’s AI Has Read 25,000 X-Rays in TB Screening
Google says an AI tool built on its model has read 25,000+ chest X-rays in about 40 African clinics, as Indonesia tunes MedGemma for TB screening.
AI Eye Exams Closed a Youth Diabetes Screening Gap, Study Says
A Johns Hopkins trial found AI eye exams at diabetes clinics lifted youth screening to 98-99.5% and closed a White v non-White gap - but only in Baltimore.
Personalised mRNA Therapy Cuts Melanoma Recurrence or Death Risk 42%
In a 1,137-patient phase 3 trial, intismeran plus Keytruda cut the risk of melanoma recurrence or death by 42%. Survival data are not yet mature.
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.
